It has been approved by the US FDA for the treatment of complicated intra-abdominal infections (cIAIs), complicated skin and skin structure infections (cSSSIs) 1 and communityacquired bacterial pneumonia (CABP). 2 Notwithstanding these indications, tigecycline's pharmacological and microbiological profiles encourage physicians' use of the drug for off-label indications. 3, 4 The definition of off-label use is not limited to prescribing an antibiotic for an indication that is not approved by regulatory authorities. The off-label use of a medication may include other parameters such as age, severity of illness, dose and route of administration and drug combinations, among others. 5 Taking this into consideration, we have evaluated some characteristics of a group of patients treated with tigecycline for the approved indications (cSSSIs, cIAIs and CABP) and compared them with the patients included in the randomized clinical trials (RCTs) developed by the pharmaceutical company for each indication.
Between 16 The institutions participating in the LatinUser Project reported a total of 209 patients. Only 66 of them (31.6%) received tigecycline for approved indications (cSSSIs, n ¼ 38, 18.2%; cIAIs, n ¼ 18, 8.6%; and CABP, n ¼ 10, 4.8%). Fifty-six patients (84.8%) were admitted to an ICU. The mean APACHE II score at admission was 14.5 (range 10 -30). In patients with CABP the mean CURB-65 score was 4 (range 2 -4). Among patients with cSSSIs and cIAIs, 64.3% of infections were nosocomial infections (36/56).
All patients received previous antibiotic therapy; in 57.6% of cases for !3 days (38/66). Vancomycin, carbapenems (imipenem or meropenem) and piperacillin/tazobactam, alone or in combination, were the most frequent antibiotics previously used (60.6% of patients, 40/66).
Tigecycline and a concurrent antibiotic were used in 22 patients (33%). The most common concurrent antibiotics were antipseudomonal agents [carbapenems (imipenem or meropenem), broad-spectrum cephalosporins and ciprofloxacin]; 72.7% of patients, 16/22. Overall, attending physicians reported clinical success in 50 patients (75.8%; range 64%-86%); the comparison between our data and the data from the RCTs is shown in Table 1 .
While off-label prescribing is not illegal, and may sometimes be clinically appropriate, it does, however, raise a number of clinical, safety and ethical issues. Off-label use can be justified if there is sufficient evidence (e.g. in vitro activity, pharmacodynamics and well-designed observational studies) to suggest an overall reasonable risk-benefit ratio for a given clinical context. 5 I have demonstrated in two sequential studies that the offlabel use of tigecycline in Argentina is frequent (79% and 78% of total prescriptions), especially in ventilator-associated pneumonia due to MDR Acinetobacter spp. 3, 4 Considering the approved indications, we found that when tigecycline was used in cIAIs, cSSSIs and CABP, patients showed characteristics very different from those of patients included in the RCTs. Most of them had: (i) nosocomial infections and required hospitalization in an ICU (data not described in the RCTs); (ii) higher values of severity score index (APACHE II, CURB-65); and (iii) a high percentage of previous antibiotic use for !3 days and concurrent antibiotic use in one-third of patients (both conditions were a criterion for patient exclusion in the RCTs).
By definition, my patients have received tigecycline for approved indications, but, in most of them, within parameters of off-label use.
In summary, although RCTs are used extensively to characterize the efficacy and safety of new treatment options, the characteristics of the trial participants often do not reflect those of the wider patient population. In most cases, one or more patient subgroups (whether defined by severity of illness, source of infection, or previous and concomitant medication) would be under-represented. 
